Pirtobrutinib and Short-term Chemotherapy for Newly Diagnosed CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (pirtobrutinib and chemotherapy given for a short time) to treat chronic lymphocytic leukemia (CLL) in patients who have never been treated before. The goal is to see if this approach works well and can be given for a fixed, shorter duration than traditional treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic lymphocytic leukemia (CLL) that has never been treated before
- Your CLL does not have certain high-risk genetic features (del(17p) or TP53 mutation)
- You are physically able to take care of yourself with minimal help (ECOG score 0–2) and have manageable overall health burden (CIRS ≤ 6)
- Your kidney, liver, and blood-clotting function are adequate, and you have sufficient blood cell counts (with specific thresholds)
- You can swallow oral medications and are willing to follow study rules, including contraception if fertile
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
This trial tests a new pill, pirtobrutinib, for people 75 or older with chronic lymphocytic leukemia (CLL) who have never had treatment before. The goal is to see if it helps control the disease with manageable side effects.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
Hear when a new CLL (Chronic Lymphocytic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.